drugset / Trial / NCT07008053
BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of BR (bendamustine and zuberitamab) combined with OR (orelabrutinib and zuberitamab) in treatment-naïve patients with marginal zone lymphoma.
Timeline
- Start
- 2025-07
- Primary completion
- 2027-07
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Zuberitamab | Monoclonal antibody | 375 mg/m2 | — |